Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Viscoelastic Tool Highlighting Severity-Dependent Platelet Dysfunction in Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis.

Journal of general internal medicine·2026
Same author

Discrepancies of results for post infusion levels of extended half-life factor VIII/IX concentrates - a cause of concern, awaiting for solution.

Clinical chemistry and laboratory medicine·2026
Same author

Measurement uncertainty of ISO 17511:2020 compliant and globally standardized PT/INR test results.

Research and practice in thrombosis and haemostasis·2026
Same author

Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise.

Transfusion·2026
Same author

Measuring Direct Oral Anticoagulant Levels in Laboratory Practice: Impact of Different Storage Conditions of Blood Samples.

International journal of laboratory hematology·2025

Related Experiment Video

Updated: Jun 21, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing.

Armando Tripodi1, Veena Chantarangkul, Pier M Mannucci

  • 1Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Internal Medicine, University of Milano Medical School and IRCCS Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena Foundation, Milano, Italy. armando.tripodi@unimi.it

British Journal of Haematology
|August 8, 2009
PubMed
Summary
This summary is machine-generated.

Global coagulation tests like PT and APTT are less reliable for acquired defects. Thrombin generation assays are better suited for investigating acquired coagulopathies due to decreased pro- and anti-coagulants.

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

Area of Science:

  • Hematology
  • Clinical Coagulation

Background:

  • Acquired coagulation defects involve reduced levels of both pro-coagulant and anti-coagulant factors.
  • Traditional global coagulation tests, such as prothrombin time (PT) and activated partial thromboplastin time (APTT), may be inadequate for assessing these complex defects.

Purpose of the Study:

  • To investigate the suitability of PT and APTT for evaluating acquired coagulation defects.
  • To explore the reasons behind the limited predictive value of PT and APTT in acquired coagulopathies.
  • To highlight the advantages of thrombin generation assays in this context.

Main Methods:

  • Analysis of acquired coagulation defects using cirrhosis and the neonatal period as models.
  • Comparison of PT and APTT results with thrombin generation in the presence of thrombomodulin.
  • Hypothesizing the mechanisms by which PT and APTT respond to changes in pro- and anti-coagulants.

Main Results:

  • PT and APTT are not consistently good predictors of bleeding in acquired coagulopathies, unlike in congenital defects.
  • Cirrhosis and neonatal period exhibit normal thrombin generation with thrombomodulin despite prolonged PT and APTT.
  • PT and APTT are more sensitive to pro-coagulant levels than to the inhibition by anti-coagulants like protein C.

Conclusions:

  • PT and APTT can indicate pro-coagulant deficiency but not the balance with anti-coagulant levels in acquired defects.
  • Thrombin generation assays offer a more accurate assessment of hemostasis in acquired coagulation disorders compared to PT and APTT.